T
Tempo Therapeutics
A San Diego-based life science startup shaping the future of medicine through materials science
About Tempo Therapeutics
Tempo is a pioneering company in the field of regenerative medicine, focusing on the development of advanced materials science solutions. The company specializes in creating materials that are immune stealth, meaning they can evade the body's typical immune rejection response. These materials are also minimally invasive and precision-engineered, making them ideal for building synthetic tissue hybrids for various applications, from skin to bone to heart to brain.
Tempo serves a diverse range of clients, including medical professionals, healthcare institutions, and research organizations. The company operates in the regenerative medicine market, which is a rapidly growing sector focused on repairing or replacing damaged tissues and organs.
The business model of Tempo revolves around the development and commercialization of its proprietary materials. Revenue is generated through the sale of these materials to healthcare providers and researchers, as well as through partnerships and licensing agreements.
Tempo's innovative approach allows for fast tissue integration and controlled inflammation, making their products highly effective and versatile. The materials can be delivered through minimally invasive methods such as syringes, cannulas, or catheters, providing a significant advantage in clinical settings.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- San Diego, United States
- Employees
- 15
- Open positions
- 2
- Dealroom signal
- 62.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Sep 2024 | $0 | — | Johnson & Johnson | ↗ |
| SERIES A✓Equity / VC | Mar 2024 | $12M | $48M | Johnson & Johnson Innovation · Galaxy-Sirius Partners | ↗ |
Growth signals
Latest recorded traffic for Tempo Therapeutics is 1.8K monthly website visits, up 5.9% over the last three months. Tempo Therapeutics's team declined 21.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Johnson & Johnson Innovation- GPGalaxy-Sirius Partners
Series B and later1 investor entered at this stage
Johnson & Johnson
Other known investors2 additional known investors
University of California, Los Angeles
Small Business Innovation Research
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tempo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tempo Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.